# OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer

> **NCT04941378** · PHASE1 · WITHDRAWN · sponsor: **Abramson Cancer Center at Penn Medicine**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** OTL38
- **DEVICE:** intraoperative imaging camera system

## Key facts

- **NCT ID:** NCT04941378
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-28
- **Primary completion:** 2022-05-28
- **Final completion:** 2022-05-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to sponsor request
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04941378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04941378, "OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT04941378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*